GLP-1 receptor agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-16. Numbers and descriptions here follow the published literature rather than marketing material.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Severo-Kurilsky District (Severo-Kurilsk) Kurilsky District (Kurilsk) Yuzhno-Kurilsky District (Yuzhno-Kurilsk) Japan maintains a claim to the three islands of Kunashir, Iturup, and Shikotan, and the Habomai Islands, together called the Northern Territories. In addition, the Japanese government claims that the Kuril Islands, other than the Northern Territories and South Karafuto, are undetermined areas under international law because the San Francisco Peace Treaty does not specify where they belong and the Soviet Union did not sign it. On 8 February 2017 the Russian government gave names to five previously unnamed Kuril islands in Sakhalin Oblast: Derevyanko Island (after Kuzma Derevyanko, 43°22′8″N 146°1′3″E), Gnechko Island (after Alexey Gnechko, 43°48′5″N 146°52′1″E), Gromyko Island (after Andrei Gromyko, 46°14′1″N 150°36′1″E), Farkhutdinov Island (after Igor Farkhutdinov, 43°48′5″N 146°53′2″E) and Shchetinina Island (after Anna Shchetinina, 46°13′7″N 150°34′6″E).
The Yemeni Civil War, which began in 2014, has been one of the most heavy conflicts in history, and caused a severe humanitarian crisis. In recent years, however, there have been several efforts to achieve a peaceful resolution and bringing stability to the country. One of the most important developments in the peace process was the Stockholm Agreement, which was reached in December 2018 between the conflicting parties, the government of Yemen and the Houthi rebels. This agreement focused on implementing a ceasefire in the city of Hodeida and the areas surrounding the city. The agreement also focused on the redeployment of forces, and addressing humanitarian concerns. The agreement was seen as a significant step to alleviate the suffering of the Yemeni people and for further negotiations. Subsequently, there have been multiple rounds of talks and negotiations facilitated by the United Nations. These discussions have covered a comprehensive political solution, prisoner exchanges and the establishment of a transitional government. The main goal has been to address the causes of the conflict, foster national reconciliation and restore security and stability in Yemen. Another important development in the peace process was the Riyadh Agreement, between the Yemeni government and the Southern Transitional Council (STC) in November 2019. This agreement aimed to resolve power struggles in southern Yemen by establishing a power-sharing arrangement between the two parties.
== Bibliography == Hluchan, Stephen E.; Pomerantz, Kenneth (2005). "Calcium and Calcium Alloys". Ullmann's Encyclopedia of Industrial Chemistry. Weinheim: Wiley-VCH. doi:10.1002/14356007.a04_515.pub2. ISBN 978-3-527-30673-2.
== Lawsuits == In 2009, Pfizer resolved all but three of 35,000 claims over its withdrawn diabetes drug Rezulin for a total of about $750 million. Pfizer, which acquired rival Wyeth for almost $64 billion, paid about $500 million to settle Rezulin cases consolidated in federal court in New York, according to court filings. The company also paid as much as $250 million to resolve state-court suits. In 2004, it set aside $955 million to end Rezulin cases.
It was manipulated in such a way that it looked like it was actually a Georgian provocation that might undermine a heated status quo, and the Russians simply said no to the provocation." Around the 10th anniversary of the war in August 2018, Matthew Bryza defended Georgian president Saakashvili: "But what president in the world would not respond to his own sovereign territory being attacked by separatists or by anyone else?" He futhrter stated that "The defining moment was indeed Bucharest 2008, and that was a red flag for President Putin; the decision meant that he'd better act quickly because eventually Ukraine and Georgia are going to get NATO membership." In April 2019, former Secretary General of NATO Anders Fogh Rasmussen opined that NATO's decision not to offer a Membership Action Plan (MAP) to Georgia and Ukraine at the 2008 Bucharest summit was a "mistake" because soon after Georgia was invaded and occupied. In August 2019, Georgian artist Vakhtang Kikabidze said in an interview that he had once asked Yevgeny Primakov why Russia needed South Ossetia and Primakov's answer was "So, you will forget about Abkhazia." In August 2022, Daniel Fried said: "We knew what was coming. But we were a little bit slow to quite believe it." He further stated: "Putin wanted his war against Ukraine. And even though the U.S. successfully exposed all of Putin's provocations, he went in anyway. [...] So, to blame Saakashvili and say, well, he fell for the provocations, therefore the war is his fault is nonsense.
Sources: en.wikipedia.org
Since the 1999 publication of Good Manufacturing Practice for Active Pharmaceutical Ingredients, by the International Conference on Harmonization (ICH), GMPs now apply in those countries and trade groupings that are signatories to ICH (the EU, Japan and the U.S.), and applies in other countries (e.g., Australia, Canada, Singapore) which adopt ICH guidelines for the manufacture and testing of active raw materials.
Using various modifiers, the activity of the enzyme can be regulated, enabling control of the biochemistry of the cell as a whole. The structure of proteins is traditionally described in a hierarchy of four levels. The primary structure of a protein consists of its linear sequence of amino acids; for instance, "alanine-glycine-tryptophan-serine-glutamate-asparagine-glycine-lysine-...". Secondary structure is concerned with local morphology (morphology being the study of structure). Some combinations of amino acids will tend to curl up in a coil called an α-helix or into a sheet called a β-sheet; some α-helixes can be seen in the hemoglobin schematic above. Tertiary structure is the entire three-dimensional shape of the protein. This shape is determined by the sequence of amino acids. In fact, a single change can change the entire structure. For example, the beta chain of hemoglobin contains 146 amino acid residues; substitution of the glutamate residue at position 6 with a valine residue changes the behavior of hemoglobin so much that it results in sickle-cell disease. Finally, quaternary structure is how separately polypeptide chains interact with one another to form the final protein. This applies only to proteins composed of multiple chains, such as hemoglobin with its four subunits, whereas many others have only one chain.
=== Other conditions === Previous hand injury Ledderhose disease (plantar fibromatosis) Epilepsy (possibly due to anti-convulsive medication) Higher-than-average fasting blood glucose level Diabetes mellitus HIV Macrophallism Previous myocardial infarction
In February 1601, Captain James Lancaster, while commanding the first English East India Company fleet en route to Sumatra, landed on the northern coast of Madagascar specifically to obtain lemons and oranges for his crew to stop scurvy. Captain Lancaster conducted an experiment using four ships under his command. One ship's crew received routine doses of lemon juice while the other three did not receive such treatment. As a result, members of the non-treated ships started to contract scurvy, with many dying as a result. It is possible that Lancaster learnt about the importance of fresh fruit from his previous voyages. Researchers have estimated that during the Age of Exploration (between 1500 and 1800), scurvy killed at least two million sailors. Jonathan Lamb wrote: "In 1499, Vasco da Gama lost 116 of his crew of 170; In 1520, Magellan lost 208 out of 230; ... all mainly to scurvy." A 1609 book by Bartolomé Leonardo de Argensola recorded several different remedies for scurvy known at this time in the Moluccas, including a kind of wine mixed with cloves and ginger, and "certain herbs". The Dutch sailors in the area were said to cure the same disease by drinking lime juice. In 1614, John Woodall, Surgeon General of the East India Company, published The Surgion's Mate as a handbook for apprentice surgeons aboard the company's ships. He repeated the experience of mariners that the cure for scurvy was fresh food or, if not available, oranges, lemons, limes, and tamarinds.
==== Functional problems ==== Functionally, small bowel dysmotility, delayed gastric emptying and delayed colonic transit are commonly related to EDS. These changes in transit speeds within the gastrointestinal system can cause a host of symptoms, including abdominal pain, bloating, nausea, reflux symptoms, vomiting, constipation, and diarrhea. Some studies also suggest problems with the liver, which is, in large part, responsible for bilirubin conjugation. Although research in this area is sparse, patients with joint hypermobility were found to have higher rates of indirect hyperbilirubinemia than control groups.
Sources: en.wikipedia.org
=== Ullrich congenital muscular dystrophy === Ullrich congenital muscular dystrophy (UCMD) is a condition that primarily affects the function of skeletal muscles. UCMD has been associated with mutations in the COL6A1, COL6A2, and COL6A3 gene. The most common pattern of inheritance for UCMD is autosomal recessive, although an autosomal dominant pattern of inheritance is observed in rare cases.
=== Appearance === Natural casing sausages are distinguishable from collagen or cellulose casings because of their irregularity, although high-quality sheep and lamb casings can be almost indistinguishable from a collagen casing as they have no noticeable imperfections. The main difference is in the way they are twisted and linked which affects the appearance of the final product and makes it easy to differentiate a hot dog using natural sheep or lamb casing vs collagen casing. The size and usage of natural casings relate to the animal from which they are derived, the narrowest being lamb followed by sheep followed by pig followed by beef. The size range for lamb is 14 mm to 28 mm in diameter (which is how casings are graded), the size range for sheep is 16 mm to 32 mm in diameter, the size range for pig is 28 mm to 58 mm in diameter, the size range for beef is 43 mm to 65 mm, although beef bung caps (which are not derived from the small intestine) have a size range of 115 mm to 130 mm.
=== Clotted samples === Coagulation within the sample leads to undercounting, because the analyzer samples the liquid part of the blood, while some of the platelets remain in the tube, trapped in the clot. Overfilling the sample, or inadequately mixing with anticoagulant, may allow small clots to form. Unlike platelet clumps, clots usually cannot be detected by reviewing the peripheral blood smear, but may be detected by probing with wooden sticks, including checking under the cap.
== Further reading == Savulescu, Julian; Bostrom, Nick (2009). Human enhancement. Oxford: Oxford University Press. ISBN 978-0-19-929972-0. Savulescu, Julian; ter Meulen, Ruud; Kahane, Guy (2011). Enhancing human capacities. Chichester: Wiley-Blackwell. ISBN 978-1-4051-9581-2. Michael Bess (2015). Our Grandchildren Redesigned: Life in the Bioengineered Society of the Near Future. Beacon Press. ISBN 978-0-8070-5217-4. Bateman, Simone; Gayon, Jean; Allouche, Sylvie; Goffette, Jérôme; Marzano, Michela (2015). Inquiring into Human Enhancement: Interdisciplinary and International Perspectives (1 ed.). London: Palgrave Macmillan. ISBN 978-1-137-53006-6. Edwards, Gary (2016). "Enhancement". Encyclopedia of Global Bioethics. Springer International Publishing. pp. 1121–1130. doi:10.1007/978-3-319-09483-0_172. ISBN 978-3-319-09483-0. Jotterand, Fabrice; Ienca, Marcello (2024). The Routledge Handbook of the Ethics of Human Enhancement. New York: Routledge. ISBN 978-0-367-61579-6.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.